DRUG DEVELOPMENT

More in DRUG DEVELOPMENT

• AI emerges as a game-changer for faster, smarter clinical trials

  Brand Connect Initiative

  

• Partnerships as catalysts: The role of collaborations in advancing pharmaceutical innovation

  ​Steering the complex regulatory space is among the most daunting aspects of pharmaceutical development. Partnerships can play a crucial role in enhancing regulatory compliance and ensuring product quality. When pharmaceutical firms collaborate with companies with a deep understanding of regulatory requirements and quality assurance practices, they can streamline their approval processes and avoid costly delays

  • Exclusive

  

• Sanofi partners with OpenAI, Formation Bio on AI-driven drug development

  ​Major drugmakers are using artificial intelligence to find patients for clinical trials quickly, or to reduce the number of people needed to test medicines, both accelerating drug development and potentially saving millions of dollars.

  

• Parexel, Palantir collaborate to enhance, accelerate delivery of safe, effective clinical trials

  ​Under the collaboration, Parexel will leverage Palantir’s Foundry and Artificial Intelligence Platform (AIP) to further power its clinical data platform, focused on driving clinical trial efficiency while maintaining the highest level of safety and regulatory rigour.

  

• Study gives more insight into molecular causes of different functions of opioid receptors

  A worldwide team of experts investigated the molecular mechanisms of these active compounds. The study, conducted by Dr Matthias Elgeti, a biophysicist at Leipzig University, in partnership with research groups from the United States and China, has recently been published in the journal Nature.

  

• IISER Bhopal develops technology to link chemical tags to proteins for facilitating drug development

  Proteins are extremely prone to loss of function when treated with chemical reagents. However, the novel technique eliminates this problem. This technology is called ‘Baylis Hillman orchestrated Protein Aminothiol Labelling’ (BHoPAL) which efficiently tags chemicals to proteins without compromising their function.

  

• Healthcare: Gen AI speeds up workflows, drug development

  “Now, with Gen AI (generative AI), it could be game changing, it can look at all these documents and can expedite the whole decision-making process,” says Bharat Kumar Damalcheruvu, head of business development & strategy for the Americas, Gen AI Office, at Cognizant.

  

• Lupin, Zydus partners for Co-marketing chronic liver disease treatment in India

  According to the agreement, Lupin is granted semi-exclusive rights to co-promote the product in India using the LINVAS brand. Zydus has introduced the drug with the brand names Lipaglyn and Bilypsa and will maintain its marketing efforts for these products.

  

• Venus Remedies receives UK market approval for Bleomycin 15,000 IU

  Venus Remedies holds a total of 15 MA for Bleomycin products across the globe. Bleomycin 15,000 IU has a wide range of applications, including the treatment of certain types of squamous cell carcinomas in areas like the head and neck, cervix, and external genitalia.

  

• Brazil scientists developing new 'vaccine' for cocaine addiction

  Dubbed "Calixcoca," the test vaccine, which has shown promising results in trials on animals, triggers an immune response that blocks cocaine and crack from reaching the brain, which researchers hope will help users break the cycle of addiction.

  

• Merck discontinues some cancer drug development with China's Sichuan Kelun

  The move comes days after Merck said it would pay Daiichi Sankyo $5.5 billion to jointly develop three of its candidate cancer drugs in a deal that could be worth up to $22 billion for the Japanese firm. Merck is aiming for at least $6 billion in revenue from its oncology business in the fiscal year ending March 31, 2026, which would represent about a five-fold increase over a three-year period.